# Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

> **NCT03288129** · PHASE4 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 54 (actual)

## Conditions studied

- Partial Onset Seizures
- Secondarily Generalized Seizures
- Primary Generalized Tonic-Clonic Seizures

## Interventions

- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT03288129
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2021-04-27
- **Final completion:** 2021-04-27
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288129, "Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03288129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*